Latest News and Press Releases
Want to stay updated on the latest news?
-
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
-
Shares of Yumanity to commence trading on Nasdaq under new ticker symbol “YMTX” on December 23, 2020 $33.6 million common stock private investment in public equity (“PIPE”) transaction closes...
-
Leading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus Proteostasis...
-
BOSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for...
-
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
-
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
-
Strategic Alliance Combines Yumanity’s Innovative Drug Discovery Platform with Merck’s Development and Commercialization Expertise in Neuroscience Merck Gains Exclusive Rights to Two Novel Yumanity...